Targeting the Akt/mTOR pathway in Brca1-deficient cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer susceptibility gene 1 (Brca1) plays a crucial role in mammary tumorigenesis.
• The precise mechanisms by which Brca1 deficiency drives cancer development remain unclear.
• Akt kinase activation is a frequent event in human cancers, including breast cancer.

Purpose of the Study:

• To investigate the role of the Brca1/Akt pathway in tumorigenesis.
• To analyze the correlation between Brca1 expression and Akt activation in human breast cancer samples.
• To evaluate the therapeutic potential of targeting Akt and mTOR pathways in Brca1-deficient cancers.

Main Methods:

• Analysis of Brca1 and Akt expression in human breast cancer samples.
• In vitro studies involving knockdown of Akt1 using short-hairpin RNA in Brca1 mutant cells.
• In vivo studies using mouse models to assess tumor formation after Akt1 depletion.
• Treatment of Brca1-deficient mouse models with a mammalian target of rapamycin (mTOR) inhibitor, Palomid 529.

Main Results:

• Reduced Brca1 expression strongly correlated with increased Akt phosphorylation in human breast cancers.
• Akt1 knockdown inhibited proliferation and tumor formation in Brca1-deficient cells and mouse models.
• Palomid 529 significantly suppressed Brca1-deficient tumor growth by inhibiting both Akt and mTOR signaling.

Conclusions:

• Akt activation is implicated in Brca1-deficiency-mediated tumorigenesis.
• Targeting the mTOR pathway, alongside Akt, offers a potential therapeutic strategy for Brca1-deficient breast cancers.